头颈癌幸存者慢性放疗相关吞咽困难的家庭强化治疗可行性及依从性:HIT-CRAD试验
结果显示各组总体依从性和运动依从性均高于75%,家庭HD-tDCS安全可行,副作用为轻中度。
要点
- 家庭高强度力量与技能训练联合HD-tDCS在慢性放疗相关吞咽困难患者中可行。
- 各组总体依从性和运动依从性均保持在75%以上。
- 真与假HD-tDCS均安全、可行且耐受良好,副作用为轻中度。
核心结论
- 本研究证实了在高容量力量与技能训练中联合HD-tDCS对慢性放疗相关吞咽困难患者的可行性。
- 主动的依从性支持因素有助于该人群实现高依从性。
- 真与假HD-tDCS均安全、可行且耐受良好。
研究设计与样本
- 第1组进行8周力量训练;第2组和第3组结合4周力量训练与4周技能训练;第3组在训练期间接受HD-tDCS,第2组接受假HD-tDCS。
主要发现
- 各组总体依从性和运动依从性均保持在75%以上。
- 家庭HD-tDCS安全可行,副作用为轻中度(刺痛、瘙痒或烧灼感)。
- 力量训练运动的中位运动表现水平范围为94%至100%。
临床怎么用
- 对于头颈癌根治性放化疗后慢性放疗相关吞咽困难患者,可考虑家庭高强度力量与技能训练联合HD-tDCS。
- 实施过程中应主动提供依从性支持因素以促进高依从性。
- 家庭HD-tDCS副作用为轻中度,耐受性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The HIT-CRAD trial (ISRCTN57028065) is the first to combine home-based non-invasive brain stimulation with high-volume strength and skill training over 8 weeks in patients with chronic radiation-associated dysphagia (CRAD) following primary (chemo)radiotherapy for head and neck cancer. METHODS: Fifty-four patients were randomized into three groups. Group 1 performed 8 weeks of strength training. Groups 2 and 3 combined 4 weeks of strength training with 4 weeks of skill training. Group 3 received high-definition transcranial direct current stimulation (HD-tDCS) during training. Group 2 received sham HD-tDCS. RESULTS: Overall adherence and exercise adherence remained above 75% across all groups. Home-based HD-tDCS proved safe and feasible, with mild to moderate side effects (tingling, itching, or burning). Median exercise performance levels for strength training exercises ranged from 94% to 100%. CONCLUSIONS: This study confirms the feasibility of high-volume strength and skill training with HD-tDCS in patients with C-RAD. Proactive adherence-supporting factors facilitate high adherence in this population. Both real and sham HD-tDCS proved safe, feasible, and well tolerated. TRIAL REGISTRATION: International Standard Randomized Controlled Trials Number (ISRCTN) registry ID ISRCTN57028065.
引用
- Massonet H, Goeleven A, Nuyts S, et al. Feasibility and Adherence to Home-Based Intensive Treatment Programs for Chronic Radiation-Associated Dysphagia in Head and Neck Cancer Survivors-The HIT-CRAD Trial. Head Neck. 2025. PMID: 41420436. doi:10.1002/hed.70136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。